Human DNA Exonuclease TREX1 Is Also an Exoribonuclease That Acts on Single-stranded RNA*

Received for publication, March 23, 2015, and in revised form, April 7, 2015. Published, JBC Papers in Press, April 8, 2015, DOI 10.1074/jbc.M115.653915

Fenghua Yuan1*, Tanmay Dutta1, Ling Wang†, Lei Song‡, Liya Gu§, Liangyue Qian¶, Anaid Benitez‖, Shunbin Ning††, Arun Malhotra‡‡, Murray P. Deutscher¶¶, and Yanbin Zhang†††

From the 1Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, Florida 33136, the 2Department of Medicine, Center for Inflammation, Infectious Diseases, and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee 37614, and the 3Graduate Center for Toxicology, University of Kentucky College of Medicine, Lexington, Kentucky 40536

Background: 3′ repair exonuclease 1 (TREX1) is a DNase involved in autoimmune disorders and the antiviral response.

Results: TREX1 also degrades single-stranded RNA or RNA in a RNA/DNA hybrid molecule.

Conclusion: TREX1 is a human homolog of Escherichia coli RNase T.

Significance: The novel RNase activity of TREX1 is crucial for understanding its physiological role.

3′ repair exonuclease 1 (TREX1) is a known DNA exonuclease involved in autoimmune disorders and the antiviral response. In this work, we show that TREX1 is also a RNA exonuclease. Purified TREX1 displays robust exonuclease activity that degrades single-stranded, but not double-stranded, RNA. TREX1-D200N, an Aicardi-Goutieres syndrome disease-causing mutant, is defective in degrading RNA. TREX1 activity is strongly inhibited by a stretch of pyrimidine residues as is a bacterial homolog, RNase T. Kinetic measurements indicate that the apparent Km of TREX1 for RNA is higher than that for DNA. Like RNase T, human TREX1 is active in degrading native tRNA substrates. Previously reported TREX1 crystal structures have revealed that the substrate binding sites are open enough to accommodate the extra hydroxyl group in RNA, further supporting our conclusion that TREX1 acts on RNA. These findings indicate that its RNase activity needs to be taken into account when evaluating the physiological role of TREX1.

3′ repair exonuclease 1 (TREX1)3 is the most abundant 3′ to 5′ DNA exonuclease in mammalian cells (1–3). Mutations in TREX1 cause autoimmune disorders, including Aicardi-Goutieres syndrome (AGS) type 1, systemic lupus erythematosus, chilblain lupus, and retinal vasculopathy with cerebral leukodystrophy (4–8). Failure to degrade cytosolic DNA was believed to be the principal cause of TREX1-mediated autoimmune diseases (9–11). Additionally, recent data showed that defects in TREX1 also conferred resistance to RNA viruses including human immunodeficiency virus (HIV), vesicular stomatitis virus, influenza virus, West Nile virus, and Sendai virus (12, 13).

Intriguingly, TREX1 resembles bacterial RNase T, a founding member of the DEDD superfamily of exonucleases, not only in its primary sequence (1, 14), but also in that both TREX1 and RNase T are active as homodimers (1, 15, 16). Inasmuch as RNase T plays an important role in Escherichia coli RNA metabolism including rRNA end turnover and 3′ maturation of tRNAs and rRNAs, and also exhibits high affinity and robust exonuclease activity on DNA like all other members of the DEDD superfamily (14, 17), we speculated that TREX1 also might have exoribonuclease activity. This was of particular interest because of the involvement of TREX1 in the autoimmune response to cellular nucleic acids as well as its immune response to RNA viruses (9, 10, 12, 13). However, in earlier work exoribonuclease activity was not detected for TREX1 (1).

Nevertheless, we thought it would be worthwhile to reevaluate the biochemical activity of TREX1. To do this, we designed a novel protocol to overexpress and purify full-length human TREX1 from insect cells. In the previous work, TREX1 was expressed in the bacterium, E. coli, and was not the full-length protein (1, 18). Using the insect-cell purified protein, we demonstrate here that TREX1 has 3′ to 5′ exoribonuclease activity on single-stranded RNA (ssRNA) and on DNA/RNA hybrids, but not on double-stranded RNA (dsRNA). Interestingly, human TREX1 and E. coli RNase T share strikingly similar catalytic properties, and based on our observations, we believe they are homologs. Possible roles for the exoribonuclease activity of TREX1 in cellular RNA metabolism and in immunity to RNA viruses are discussed.

Experimental Procedures

Protein Expression, Fractionation, and Purification—The identity of human TREX1 cDNA was confirmed by sequencing and found to match exactly the open reading frame of NCBI Reference Sequence NM_033629 (isoform b) (2). The TREX1-D200N mutant was created by using the QuikChange site-directed mutagenesis kit (Agilent Technologies). Overexpression of non-tagged TREX1 was carried out in insect High Five cells using the Bac-to-Bac expression system (Invitrogen). Expression of TREX1 was confirmed by Western blot analysis us-
ing a Pierce ECL kit (Pierce). Antibody against TREX1 was purchased from Santa Cruz Biotechnology (Dallas, TX) (SC-271870).

Upon expression of human TREX1, the insect cells were resuspended in a hypotonic buffer (20 mM Hepes-KOH, pH 7.5, 0.5 mM MgCl₂, 5 mM KCl, 5 mM β-mercaptoethanol, and a mixture of protease inhibitors (19)). Nuclei were separated from the cytoplasm of insect cells by homogenization on ice using 10 strokes of a Dounce homogenizer followed by centrifugation at 4,200 rpm (Beckman Coulter rotor JLA-10.500) at 4 °C for 6 min. The nuclear pellet was re-suspended in a cold hypertonic buffer (20 mM Hepes-KOH, pH 7.5, 10% sucrose, 500 mM NaCl, 5 mM β-mercaptoethanol, and the mixture of protease inhibitors), incubated on ice for 10 min, and centrifuged at 12,000 rpm (Beckman Coulter rotor JA-25.500) at 4 °C for 30 min. The precleaned nuclei were then resuspended in the hypertonic buffer containing 0.5% Nonidet P-40, incubated on ice for 10 min, and centrifuged at 16,000 rpm (Beckman Coulter rotor JA-25.500) at 4 °C for 1 h.

The supernatant fraction containing TREX1 was desalted to 100 mM KCl in buffer Q (50 mM KPO₄, pH 7.4, 0.5 mM EDTA, 0.01% Nonidet P-40, 10% glycerol, 2 mM DTT and protease inhibitors) and loaded onto a 5-ml Q-Sepharose column. The flow-through from the Q-Sepharose column was directly loaded onto a 1-ml Mono S column (GE Healthcare) in buffer Q. The Mono S column was then resolved using a 30-ml 100 to 500 mM KCl gradient. TREX1 was eluted at 280 mM KCl. The pooled TREX1 was concentrated by ultracentrifugation and loaded on a Superdex 200 column (GE Healthcare) in buffer Q with 160 mM KCl. Depending on the purity of TREX1 after Superdex chromatography, it can be further purified on a ssDNA cellulose column using 330 mM KCl for elution from the column. TREX1 protein was followed by SDS-PAGE and Western blot analysis throughout the purification process. Mutant TREX1-D200N was purified using the same protocol as for the wild-type protein. Protein concentration was determined by the Coomassie (Bradford) Protein Assay Reagent (Pierce). The purified protein was stored in aliquots at −80 °C.

FIGURE 1. Purified human TREX1 displays exoribonuclease activity on ssRNA. A, SDS-PAGE and Western blots of fractionated TREX1-containing extracts (40 μg each lane). Salt + Nonidet P-40 indicates the TREX1 protein samples after osmotic and detergent treatments. Arrows point to TREX1. Protein markers in kilodaltons are indicated. B, SDS-PAGE and Western analysis of the purified WT and D200N TREX1 proteins. The PAGE gel was stained with Coomassie Brilliant Blue R-250. Arrows point to the purified TREX1. Protein markers in kilodaltons are indicated. C, Titration of TREX1-WT and TREX1-D200N proteins on a 20-nucleotide ssRNA substrate (2 nM) labeled at its 5’ end by [γ-32P]ATP using T4 polynucleotide kinase. Reaction time is 10 min. Arrows point to positions of the substrate and a 10-nt standard. % Sub indicates the percentage of the remaining substrate. D, Activity of TREX1-WT and D200N on a 4-nucleotide poly(A) RNA substrate (2 nM) labeled at its 5’ end. Reaction time is 10 min. Arrows point to position of the 4-nt substrate and positions of the 2- and 3-nt standards.
Oligonucleotide Substrates and Exonuclease Assays—RNA and DNA oligos were synthesized by Integrated DNA Technology and Sigma, respectively. The sequence of the 20-nucleotide single-stranded RNA (ssRNA) is 5’-H11032-GACGCUGC-CGAAUUCUACCA-3’. The sequence of the 20-nucleotide ssDNA is 5’-H11032-GACGCTGCCGAATTCTACCA-3’. We also used poly(A)_{17}, poly(U)_{17}, poly(C)_{17}, and poly(A)_{4} RNA oligos (20) and poly(dA)_{17}, poly(dT)_{17}, and poly(dC)_{17} DNA oligos. All oligos were \(^{32}P\)-labeled at their 5’ end using phage T4 polynucleotide kinase (New England Biolabs) and [\(\gamma^{32}P\)]ATP. For nuclease assays, a specified amount of RNA or DNA substrate was incubated with an indicated amount of protein in a 5-μl reaction mixture containing 25 mM Hepes-KOH, pH 7.6, 1 mM DTT, 3 mM MgCl₂, 6.5% glycerol, 120 μg/ml of BSA, and 100 mM KCl. After incubation for the specified time at 37 °C, the reaction was terminated by adding 5 μl of sequencing dye with 0.2% SDS and denaturing at 90 °C for 3 min, followed by resolution using a 20% denaturing sequencing gel and analyzed by autoradiography.

![Image of TREX1 action on RNA and RNA/DNA hybrid substrates.](image)

**FIGURE 2.** TREX1 action on RNA and RNA/DNA hybrid substrates. The experiments were done using 16 nM purified human TREX1 for RNA, the indicated oligo substrates (2 nM), and an increasing incubation time. Arrows point to substrate position and 1-nt standard. % Sub indicates the percentage of remaining substrate. P in a circle and stars indicate the \(^{32}P\) labeling. Green, RNA; black, DNA.

![Image of Effect of metal ions on the exonuclease activity of TREX1.](image)

**FIGURE 3.** Effect of metal ions on the exonuclease activity of TREX1. The experiments were done using 16 nM purified human TREX1 for RNA and 1 nM for DNA, and the indicated oligo substrates (2 nM). The cations were added to the reaction mixture at a final concentration of 3 mM. Incubation time is shown on the top. % Sub indicates the percentage of the remaining substrate. P indicates the \(^{32}P\) labeling.
Determination of Kinetic Parameters—To measure kinetic parameters, the analyses were repeated three times using increasing amounts of the 20-nt ssRNA (1 nM, 10 nM, 100 nM, 1 μM, and 10 μM) or ssDNA substrate (1, 3, 9, 27, 81, and 243 nM). In the presence of TREX1 (16 nM for ssRNA and 0.4 nM for ssDNA), the reaction was carried out for 20 min at 37 °C. Data were fitted to the Michaelis-Menten equation:

\[ \frac{v}{V_{\text{max}}} = \frac{[S]}{K_m + [S]} \]

where \( v \) is the reaction rate and \( [S] \) is the concentration of substrate. \( K_m \) and \( V_{\text{max}} \) were determined by plotting \( v \) against \( [S] \) using Origin software through nonlinear curve fitting. \( k_{\text{cat}} \) was calculated by \( \frac{V_{\text{max}}}{[E]} \), where \([E]\) is the enzyme concentration. Quantitation of the nucleic acid excision was carried out using Image J.

Nuclease Assay on tRNA—The reactions were carried out with the addition of 4 nM TREX1 protein and 9.3 μM of a mixture of tRNA-CC[H]As (21). The 30-μl reaction mixtures were incubated at 37 °C for 30 min. The reaction was stopped by the addition of 150 μl of 0.5% (w/v) yeast RNA and 200 μl of 10% trichloroacetic acid. The sample was placed in ice for 30 min and then centrifuged at 16,000 × g for 15 min at 4 °C. The radioactivity in 200 μl of the supernatant fraction was determined by liquid scintillation counting using a LS 6500 multipurpose scintillation counter (Beckman Coulter, Inc.).

Results
Purification of Non-tagged Human TREX1 Protein—To examine the nuclease activity of native human TREX1, we developed a simple protocol for enriching and purifying the non-tagged, full-length protein from insect cells in which it was overexpressed (Fig. 1A). Isolated nuclei, which contain a large amount of TREX1 (Fig. 1A), were treated with a high salt concentration (500 mM NaCl), which results in nuclear shrinkage and forces most nuclear matrix proteins out of the nuclei. The “shrunk” nuclei were then treated with 0.5% Nonidet P-40 and 500 mM salt for release of nuclear membrane-associated and chromatin-associated proteins. This procedure greatly enriches the TREX1 protein sample before column purification (Fig. 1A, compare salt + Nonidet P-40 lanes with nuclear lanes).
The non-tagged TREX1-WT and TREX1-D200N mutant proteins were then purified to homogeneity using Q-Sepharose, Mono S, Superdex 200, and ssDNA columns. Western analysis confirmed that both homogeneous proteins were indeed TREX1 (Fig. 1B).

**Human TREX1 Has Exoribonuclease Activity**—After verifying the DNA exonuclease activity of the purified protein (see examples in Figs. 3, 4A, and 5A), we investigated whether TREX1 also has ribonuclease activity by incubating the protein with a 5’-end labeled 20-nt long RNA (see “Experimental Procedures” for sequence). As shown in Fig. 1C, TREX1 showed distributive exoribonuclease activity on this RNA substrate that increased with increasing concentrations of enzyme. At the highest levels of TREX1 protein (16 and 32 nM), almost all of the RNA oligo was converted to shorter fragments due to removal of residues from its 3’ end. In contrast, the D200N mutant of TREX1, which lacks DNA exonuclease activity and leads to AGS disease (9, 10, 22), is completely defective in shortening

---

**TABLE 1. Kinetic constants of TREX1**

| Nucleic Acids Substrate | $K_m$ (μM) | $k_{cat}$ (s$^{-1}$) | $k_{cat}/K_m$ (s$^{-1}$μM$^{-1}$) |
|-------------------------|------------|----------------------|----------------------------------|
| ssRNA                   | 5.28 ± 0.02| 0.25 ± 0.01          | 0.047                            |
| ssDNA                   | 0.22 ± 0.02| 0.30 ± 0.02          | 1.36                             |

**FIGURE 5.** Kinetic analysis of TREX1 on ssRNA and ssDNA and comparison of its DNA and RNA exonuclease activity. A, TREX1 activity on 20-nucleotide ssDNA (black) or ssRNA (green) substrate (2.4 μM). The reaction time is 10 min. Arrows point to substrate position and position of GMP. % Sub indicates the percentage of remaining substrate. P in a circle indicates the $^{32}$P labeling. B, kinetic measurement of TREX1. In the presence of 16 nM TREX1, ssDNA, or ssRNA were added at varying concentrations (“Experimental Procedures”) in a 20-min reaction. Data were fitted to the Michaelis-Menten equation and $K_m$ and $k_{cat}$ were calculated as described under “Experimental Procedures.” C, activity of TREX1 on tRNA. 4 nM TREX1 protein was incubated with 9.3 μM tRNA-CC$[^{3H}]$A at 37°C for 30 min. The radioactivity in 200 μl of the supernatant fraction was determined by liquid scintillation counting. Error bars, standard deviation.
the ssRNA substrate (Fig. 1C). Inasmuch as the WT and mutant proteins were purified using the same procedure, these data also indicate that the RNase activity is a property of TREX1 and not a contaminating protein. Additionally, an N-terminal hexahistidine-tagged version of TREX1 that was purified through a different protocol (nickel and Mono S columns) shows similar RNase activity (data not shown).

Under the incubation conditions used in Fig. 1C, most of the degradation products derived from the 20-nt ssRNA substrate were longer than 10 nucleotides. To examine whether TREX1 also can degrade a small RNA substrate, we incubated TREX1 with a 4-nucleotide oligo, A₄ (Fig. 1D). Although TREX1 is about 2–3-fold less active on the 4-nucleotide substrate than the 20-nucleotide RNA (compare Fig. 1, C with D), it effectively shortens A₄ to A₃ and A₂, indicating that TREX1 can digest even very small RNAs. Again, the D200N mutant is completely defective in shortening the A₄ substrate (Fig. 1D), confirming that the activity on A₄ is due to TREX1.

**TREX1 Cleave the RNA in a RNA/DNA hybrid, but Is Inactive on Double-stranded RNA**—In early work, TREX1 was shown to have strong exonuclease activity on ssDNA (18). To determine whether TREX1 also can degrade dsRNA, we examined its activity on a variety of substrates using 16 nM TREX1. Although TREX1 rapidly degrades ssRNA in a time-dependent manner, it is inactive on the dsRNA counterpart with no loss of substrate even after 20 min of incubation (Fig. 2). This observation is similar to what was reported for *E. coli* RNase T (23), another exoribonuclease of the DEDD family. In contrast, TREX1 is able to degrade the RNA strand in an RNA/DNA hybrid molecule, although the activity is lower than that on ssRNA. It is likely that RNA degradation in the DNA-RNA hybrid is due to release of ssRNA following rapid degradation of the DNA strand, because, as shown in Fig. 2, the DNA strand is completely degraded in 2 min, whereas degradation of the RNA strand is just beginning at that time.

As previously observed for its DNA exonuclease activity (Fig. 3, bottom panel, and Ref. 18), TREX1 requires Mg²⁺ for optimal RNase activity (Fig. 3, top panel). Other cations, Mn²⁺, Co²⁺, Zn²⁺, Cu²⁺, and Ca²⁺ are unable to stimulate activity when present at 3 mM.

The Exoribonuclease Activity of TREX1 Displays a Dramatic Base Specificity—*E. coli* RNase T is known to display strong base specificity and to discriminate against pyrimidine nucleotides (23). Consequently, we investigated the action of TREX1 on ssRNA oligos with different base compositions. In contrast to its DNA exonuclease activity, which acts almost equally on dC₁₇, T₁₇, and dA₁₇ (Fig. 4A), the RNase activity of TREX1 is very sequence dependent. As shown in Fig. 4B, TREX1 effectively degrades an A₁₇ substrate, but exhibits very limited activity with either C₁₇ or U₁₇ substrates, removing, at most, only a few residues. Again, the D200N mutant is completely incapable of degrading A₁₇ (Fig. 4B, right panel). These findings indicate that the similarity between TREX1 and *E. coli* RNase T extends to its base specificity (23).

**TREX1 Has Lower Affinity for ssRNA Than for ssDNA**—Inasmuch as TREX1 is active on both ssDNA and ssRNA, we directly compared these two activities. As shown in Fig. 5A, TREX1 degrades both ssDNA and ssRNA in a distributive manner. However, TREX1 appears to show stronger activity on ssDNA, being ~10-fold more active on DNA under the specific experimental conditions (compare 10 and 100 nM lanes on DNA and RNA (2.4 µM), respectively, in Fig. 5A).

To determine the catalytic property, we measured the kinetic constants of TREX1 on ssRNA and ssDNA. The apparent $Kₘ$ of TREX1 for ssRNA is 5.28 µM (Fig. 5B), comparable with that of *E. coli* RNase T (10 µM) (24). This is considerably higher than the $Kₘ$ of TREX1 for ssDNA (0.22 µM, Fig. 5B, and 19 nM in Ref. 18), and again resembles *E. coli* RNase T in terms of affinity for RNA and DNA substrates (17). Interestingly, the $k_{cat}$ of TREX1 for ssRNA is very similar to that for ssDNA (Fig. 5B). Thus, the resulting overall enzyme efficiency of TREX1 for ssDNA is ~30-fold higher than for ssRNA (Fig. 5B, $k_{cat}/Kₘ$). These kinetic parameters indicate that the DNase activity of TREX1 is not dramatically stronger than its RNase activity (similar $k_{cat}$), but it is more efficient on ssDNA due to its higher substrate affinity to DNA ($Kₘ$).

**TREX1 Acts on tRNA**—RNase T plays an important role in *E. coli* tRNA end turnover and 3' maturation of tRNAs and...
rRNAs (14, 17). To determine whether TREX1 also acts on natural RNA substrates, we incubated purified TREX1 with a native tRNA sample that had been 3’ end labeled with [3H]A, an assay commonly used for RNase T (21). As shown in Fig. 5C, TREX1 efficiently removes the [3H]AMP residue from tRNA, amounting to 75% of the tRNA ends in 30 min. Essentially no AMP is removed in the absence of added enzyme. This indicates that human TREX1 is active on native tRNA, again showing that its catalytic properties are similar to those of E. coli RNase T (17).

**Discussion**

In this report, we demonstrate that the DNA exonuclease TREX1, like all other members of the DEDD superfamily of nucleases, is also an exoribonuclease. We suggest that TREX1 is a human homolog of E. coli RNase T based on the following observations: 1) TREX1 and RNase T share sequence similarity (Fig. 7) (1, 2); 2) both TREX1 and RNase T need to form a homodimer to exhibit nuclelease activity (1, 15, 16, 24); 3) TREX1 and RNase T both display exoribonuclease and DNA exonuclease activity (this study and Ref. 17 for RNase T); 4) both TREX1 and RNase T display a higher $K_m$ for ssRNA than for ssDNA (this study and Refs. 17 and 18 for RNase T); and 5) both TREX1 and RNase T discriminate against pyrimidine nucleotides for their exoribonuclease activities (this study and Ref. 23 for RNase T). Thus, TREX1 might be involved in RNA metabolism in human cells just as RNase T is in E. coli (14, 17). Indeed, our data show that human TREX1, like RNase T, is competent in trimming tRNA ends (Fig. 5C). It would be of considerable interest to further examine TREX1 for possible roles in RNA metabolism.

Analysis of the available TREX1 crystal structures reveals that the substrate binding sites are open enough to accommodate the 2’ hydroxyls in an RNA substrate (9) (Fig. 6). The closest approach between the enzyme and the 2’ positions on the nucleic acid substrate is at the 3’ end in a co-crystal structure of mouse TREX1 and a DNA substrate (9). The residue closest to the 2’ position at the 3’ end of the substrate has a short side chain (Ala-81 in mouse TREX1) and can easily accommodate a hydroxyl group. This position (residue 81) in human TREX1 is also an alanine, and sequence alignment of TREX1 homologs suggests that this may be conserved, presumably to maintain sufficient space for binding RNA substrates (Fig. 7).

Human TREX1 has three transcript variants with different lengths of extra residues at the N terminus. The highest expressed TREX1 variant in human cells is isoform b that was used in this study (2). Earlier work failed to detect the RNase activity of TREX1 (1). One likely possibility to explain this result is that the TREX1 protein expressed in the earlier work was the shortest isoform (isoform c), lacking 10 amino acids at its N terminus compared with isoform b (1, 2, 18). Such a change in TREX1 structure could affect its substrate affinity or catalytic activity considering that the active site residues (Asp-8 and Glu-10 in isoform c or Asp-18 and Glu-18 in isoform b) are conserved in all three isoforms. The catalytic activity of TREX1 expressed in human cells is isoform b that is the longest isoform and has an extra 10 amino acids at its N terminus compared with isoform c. Thus, it is possible that the longer isoform of TREX1 expressed in human cells is responsible for the RNase activity detected in these studies.

**Figure 8.** The N-terminal 1–10 truncation present in isoform c of TREX1 diminishes RNase activity. The protein concentrations of WT (isoform b, NCBI Ref. sequence NP_338599.1) and isoform c (NCBI Ref. sequence NP_009179.2) of TREX1 were adjusted so that their activities against ssDNA (2 nM) were identical. Under these same conditions their respective activities against ssRNA (2 nM) were determined. Assays were carried out at 37 °C for 20 min. Arrows point to positions of the substrate and a 1-nt standard. % Sub indicates the percentage of remaining substrate.
isoform b possesses RNase activity, and that TREX1 is between isoform b and isoform c affects primarily the RNase activity, isoform c fails to degrade the ssRNA substrate, in contrast to isoform b (Fig. 8). These data explain the previous observation (1) and suggest that the structural difference between isoform b and isoform c affects primarily the RNase activity. In this regard, it will be interesting to examine the DNase and RNase activities of the longest TREX1 isoform a (2). Nevertheless, based on our data, it is clear that TREX1 isoform b possesses RNase activity, and that TREX1 is closely related to E. coli RNase T, another nuclease that possesses both DNase and RNase activity (17).

Mutations in TREX1 are known to cause AGS1 (7, 26). Moreover, the heterotrimeric endoribonuclease, RNase H2, interacts with TREX1. Defects in the RNase H2 subunits, namely RNASEH2B, RNASEH2C, and RNASEH2A, are known to cause AGS2, AGS3, and AGS4 types of the disease, respectively (26–29). Although it is tempting to speculate that the TREX1-RNase H2 complex functions as a holonuclease enzyme in removing RNA debris that may cause the autoimmune response, it is possible that the endoribonuclease activity of RNase H2 first cuts RNA into smaller fragments and then the exoribonuclease activity of TREX1 further degrades the RNA fragments to nucleotides (Fig. 1, C and D). It is therefore conceivable that defects in RNA degradation may contribute to accumulation of RNA species and thus induce other aberrant autoimmune responses such as systemic lupus erythematosus, chilblain lupus, and retinal vasculopathy with cerebral leukodystrophy. It would be interesting to investigate whether and how the exoribonuclease activity of TREX1 and the endoribonuclease activity of RNase H2 coordinate with each other to achieve efficient RNA removal.

The DNA exonuclease activity of TREX1 was shown to be responsible for preventing HIV replication by degrading the reverse-transcribed ssDNA and hiding the virus from detection by the immune system (12, 30). Beyond the proposed DNA removal of the HIV virus in suppressing the immune response (12, 30), it is also possible, based on our observations, that TREX1 may directly degrade the single-stranded HIV RNA virus or the RNA/DNA hybrid (Fig. 2A) and contribute to suppression of HIV replication. Although it has been shown that a knock-out of TREX1 causes aberrant lysosomal biogenesis, which elicits innate immune responses and inhibits replication of RNA viruses (12, 13), it is also likely that the RNase activity of TREX1 is directly involved in degrading RNA virus and preventing it from being duplicated.

In addition to the discovery of the exoribonuclease activity of TREX1, we also describe an efficient protocol for enriching and precloning proteins that are associated with chromatin and membranes. This protocol not only makes it possible to isolate and purify high quality non-tagged human TREX1 protein for this study, but it also provides a universal strategy for isolating non-tagged membrane-bound and chromatin-bound proteins.

References

1. Mazur, D. J., and Perrino, F. W. (1999) Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′ → 5′ exoribonucleases. J. Biol. Chem. 274, 19655–19660
2. Mazur, D. J., and Perrino, F. W. (2001) Structure and expression of the TREX1 and TREX2 3′ → 5′ exoribonuclease genes. J. Biol. Chem. 276, 14718–14727
3. Höss, M., Robins, P., Naven, T. J., Pappin, D. J., Sgouros, J., and Lindahl, T. (1999) A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J. 18, 3868–3875
4. Richards, A., van den Maagdenberg, A. M., Jen, J. C., Kavanagh, D., Bertram, P., Spitzer, D., Liszewski, M. K., Barilla-Labarca, M. L., Terwindt, G. M., Kasai, Y., et al. (2007) C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 39, 1068–1070
5. Lee-Kirsch, M. A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y. A., de Silva, U., Bailey, S. L., Witte, T., Vyse, T. J., et al. (2007) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39, 1065–1067
6. Lee-Kirsch, M. A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engel, K., Pfeiffer, C., Hollis, T., Gahr, M., Perrino, F. W., Lieberman, J., and Hubner, N. (2007) A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med. 85, 531–537
7. Crow, Y. J., Hayward, B. E., Parmar, R., Robins, P., Leitch, A., Ali, M., Black, D. N., van Bokhoven, H., Brunner, H. G., Hamel, B. C., et al. (2006) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38, 917–920
8. Kavanagh, D., Spitzer, D., Kothari, P. H., Shaikh, A., Liszewski, M. K., Richards, A., and Atkinson, J. P. (2008) New roles for the major human DNA exonuclease TREX1 in TREX1 human disease. Cell Cycle 7, 1718–1725
9. Bailey, S. L., Harvey, S., Perrino, F. W., and Hollis, T. (2012) Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease. DNA Repair 11, 65–73
10. Fye, J. M., Orebaugh, C. D., Coffin, S. R., Hollis, T., and Perrino, F. W. (2011) Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome. J. Biol. Chem. 286, 32373–32382
11. Barber, G. N. (2011) Cytoplasmic DNA innate immune pathways. ImmunoL Rev. 243, 99–108
12. Yan, N., Regalado-Magdos, A. D., Stiggelbout, B., Lee-Kirsch, M. A., and Lieberman, I. (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11, 1005–1013
13. Hasan, M., Koch, J., Rakheja, D., Pattnaik, A. K., Brugarolas, J., Dozmorov, I., Levine, B., Wakeland, E. K., Lee-Kirsch, M. A., and Yan, N. (2013) Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat. Immunol. 14, 61–71
14. Zuo, Y., and Deutscher, M. P. (2001) Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. Nucleic Acids Res. 29, 1017–1026
15. Orebaugh, C. D., Fye, J. M., Harvey, S., Hollis, T., and Perrino, F. W. (2011) The TREX1 exonuclease R114H mutation in Aicardi-Goutieres syndrome and lupus reveals dimeric structure requirements for DNA degradation activity. J. Biol. Chem. 286, 40246–40254
16. Li, Z., Zhan, L., and Deutscher, M. P. (1996) Escherichia coli RNase T functions in vivo as a dimer dependent on cysteine 168. J. Biol. Chem. 271, 1133–1137

Acknowledgments—We are grateful for insightful discussions with Dr. Guo-Min Li at the University of Kentucky College of Medicine. Thanks to Dr. Fred W. Perrino at the Wake Forest School of Medicine for providing the cDNA for human TREX1, Dr. Thomas Hollis at the Wake Forest School of Medicine for inspiring us to initiate this research, and Dr. Dan Stetson at the University of Washington for providing the TREX1 knock-out MEFs.
17. Zuo, Y., and Deutscher, M. P. (1999) The DNase activity of RNase T and its application to DNA cloning. *Nucleic Acids Res.* **27**, 4077–4082

18. Mazur, D. J., and Perrino, F. W. (2001) Excision of 3′ termini by the Trex1 and TREX2 3′ → 5′ exonucleases: characterization of the recombinant proteins. *J. Biol. Chem.* **276**, 17022–17029

19. Benitez, A., Yuan, F., Nakajima, S., Wei, L., Qian, L., Myers, R., Hu, J. J., Lan, L., and Zhang, Y. (2014) Damage-dependent regulation of MUS81-EME1 by Fanconi anemia complementation group A protein. *Nucleic Acids Res.* **42**, 1671–1683

20. Dutta, T., and Deutscher, M. P. (2009) Catalytic properties of RNase BN/RNase Z from *Escherichia coli*: RNase BN is both an exo- and endoribonuclease. *J. Biol. Chem.* **284**, 15425–15431

21. Deutscher, M. P., and Ghosh, R. K. (1978) Preparation of synthetic tRNA precursors with tRNA nucleotidyltransferase. *Nucleic Acids Res.* **5**, 3821–3829

22. Lehtinen, D. A., Harvey, S., Mulcahy, M. J., Hollis, T., and Perrino, F. W. (2008) The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. *J. Biol. Chem.* **283**, 31649–31656

23. Zuo, Y., and Deutscher, M. P. (2002) The physiological role of RNase T can be explained by its unusual substrate specificity. *J. Biol. Chem.* **277**, 29654–29661

24. Zuo, Y., and Deutscher, M. P. (2002) Mechanism of action of RNase T: I. identification of residues required for catalysis, substrate binding, and dimerization. *J. Biol. Chem.* **277**, 50155–50159

25. de Silva, U., Choudhury, S., Bailey, S. L., Harvey, S., Perrino, F. W., and Hollis, T. (2007) The crystal structure of TREX1 explains the 3′ nucleotide specificity and reveals a polyproline II helix for protein partnering. *J. Biol. Chem.* **282**, 10537–10543

26. Rice, G., Newman, W. G., Dean, J., Patrick, T., Parmar, R., Flintoff, K., Robins, P., Harvey, S., Hollis, T., O’Hara, A., et al. (2007) Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. *Am. J. Hum. Genet.* **80**, 811–815

27. O’Driscoll, M. (2008) TREX1 DNA exonuclease deficiency, accumulation of single-stranded DNA and complex human genetic disorders. *DNA Repair* **7**, 997–1003

28. Rigby, R. E., Leitch, A., and Jackson, A. P. (2008) Nucleic acid-mediated inflammatory diseases. *Bioessays* **30**, 833–842

29. Reijns, M. A., and Jackson, A. P. (2014) Ribonuclease H2 in health and disease. *Biochem. Soc. Trans.* **42**, 717–725

30. Geijtenbeek, T. B. (2010) Host DNase TREX1 hides HIV from DNA sensors. *Nat. Immunol.* **11**, 979–980

31. Delano, W. L. (2002) *The PyMOL Molecular Graphics System*, version 1.4, Schrödinger, LLC, New York

32. Notredame, C., Higgins, D. G., and Heringa, J. (2000) T-Coffee: a novel method for fast and accurate multiple sequence alignment. *J. Mol. Biol.* **302**, 205–217

33. Zuo, Y., Zheng, H., Wang, Y., Chruszcz, M., Cymborowski, M., Skarina, T., Savchenko, A., Malhotra, A., and Minor, W. (2007) Crystal structure of RNase T, an exoribonuclease involved in tRNA maturation and end turnover. *Structure* **15**, 417–428

34. Robert, X., and Gouet, P. (2014) Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Res.* **42**, W320–W324